Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin

Heat shock protein 90 (Hsp90) has been demonstrated to protect oncogenic variants of signalling molecules from degradation and may consequently serve as a therapeutic target for the treatment of oesophageal cancer for which adequate therapy is often lacking. We studied the expression of Hsp90 in tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, X, Wanders, A, Wardega, P, Tinge, B, Gedda, L, Bergstrom, S, Sooman, L, Gullbo, J, Bergqvist, M, Hesselius, P, Lennartsson, J, Ekman, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634703/
https://www.ncbi.nlm.nih.gov/pubmed/19142186
http://dx.doi.org/10.1038/sj.bjc.6604855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634703/
https://www.ncbi.nlm.nih.gov/pubmed/19142186
http://dx.doi.org/10.1038/sj.bjc.6604855

Ejemplares similares